Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy | Zendy

Shen Gao | Zendy; Wu | Zendy; Ding | Zendy; Gao | Zendy; Wang | Zendy; Fan Fan | Zendy; Zhang | Zendy; Ye | Zendy; Liu | Zendy; Zhu Zhu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy

Author(s) -

Shen Gao,

Wu,

Ding,

Gao,

Wang,

Fan Fan,

Zhang,

Ye,

Liu,

Zhu Zhu

Publication year - 2011

Publication title -

international journal of nanomedicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.245

H-Index - 128

eISSN - 1178-2013

pISSN - 1176-9114

DOI - 10.2147/ijn.s23747

Subject(s) - aptamer , prostate cancer , conjugated system , cancer therapy , targeted therapy , medicine , cancer research , glutamate carboxypeptidase ii , delivery system , cancer , materials science , nanotechnology , biomedical engineering , microbiology and biotechnology , biology , composite material , polymer

miR-15a and miR-16-1 have been identified as tumor suppressor genes in prostate cancer, but their safe and effective delivery to target cells is key to the successful use of this therapeutic strategy. RNA aptamer A10 has been used as a ligand, targeting prostate cancer cells that express prostate-specific membrane antigen (PSMA). Compared with A10, the binding of the second-generation RNA aptamer, A10-3.2, to PSMA is more efficient.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research